<!DOCTYPE html><html lang="fr" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  
  
  
  <meta name="generator" content="Wowchemy 5.0.0-beta.0 for Hugo">
  

  

  
  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Team CoReDS">

  
  
  
    
  
  <meta name="description" content="BACKGROUND:Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.METHODS:In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.RESULTS:A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P&amp;lt;0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.CONCLUSIONS:Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .). ">

  
  <link rel="alternate" hreflang="fr" href="https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/">

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  

  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  
  
  <script src="/js/mathjax-config.js"></script>
  

  
  
  
  
    
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.css" integrity="sha512-1xoFisiGdy9nvho8EgXuXvnpR5GAMSjFwp40gSRE3NwdUdIMIKuPa7bqoUhLD0O/5tPNhteAsE5XyyMi5reQVA==" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.2.2/lazysizes.min.js" integrity="sha512-TmDwFLhg3UA4ZG0Eb4MIyT1O1Mb+Oww5kFG0uHqXsdbyZz9DcvYQhKpGgNkamAI6h2lGGZq2X8ftOJvF/XjTUg==" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.css">

  




  

  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="Consultation Recherche Données de Santé - CoReDS">
  <meta property="og:url" content="https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/">
  <meta property="og:title" content="Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. | Consultation Recherche Données de Santé - CoReDS">
  <meta property="og:description" content="BACKGROUND:Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.METHODS:In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.RESULTS:A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P&amp;lt;0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.CONCLUSIONS:Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .). "><meta property="og:image" content="https://www.coreds.com/images/logo_hu240a3cf0bd6402c880746328a9376fed_42031_300x300_fit_lanczos_2.png">
  <meta property="twitter:image" content="https://www.coreds.com/images/logo_hu240a3cf0bd6402c880746328a9376fed_42031_300x300_fit_lanczos_2.png"><meta property="og:locale" content="fr">
  
    
      <meta property="article:published_time" content="2017-09-01T00:00:00&#43;00:00">
    
    <meta property="article:modified_time" content="2017-09-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/"
  },
  "headline": "Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.",
  
  "datePublished": "2017-09-01T00:00:00Z",
  "dateModified": "2017-09-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Mas Jean-Louis"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Consultation Recherche Données de Santé - CoReDS",
    "logo": {
      "@type": "ImageObject",
      "url": "https://www.coreds.com/images/logo_hu240a3cf0bd6402c880746328a9376fed_42031_192x192_fit_lanczos_2.png"
    }
  },
  "description": "BACKGROUND:Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.METHODS:In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.RESULTS:A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P\u0026lt;0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.CONCLUSIONS:Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .). "
}
</script>

  

  


  
  
  
  
  
    <script src="https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.js" integrity="sha256-5VhCqFam2Cn+yjw61zbBNrbHVJ6SRydPeKopYlngbiQ=" crossorigin="anonymous"></script>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.css" integrity="sha256-zQ0LblD/Af8vOppw18+2anxsuaz3pWYyVWi+bTvTH8Q=" crossorigin="anonymous">
  
  <script>
  window.addEventListener("load", function(){
    window.cookieconsent.initialise({
      "palette": {
        "popup": {
          "background": "#2962ff",
          "text": "rgb(255, 255, 255)"
        },
        "button": {
          "background": "rgb(255, 255, 255)",
          "text": "#2962ff"
        }
      },
      "theme": "classic",
      "content": {
        "message": "Ce site utilise des cookies pour vous assurer la meilleure expérience.",
        "dismiss": "Accepter",
        "link": "En savoir plus",
        "href": "https://www.cookiesandyou.com"
      }
    })});
  </script>



  





  <title>Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. | Consultation Recherche Données de Santé - CoReDS</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper  ">

  
  
  
  
    <script>const isSiteThemeDark = false;</script>
  
  
  <script src="/js/load-theme.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Rechercher</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Recherche..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  <div class="page-header">
    











  


<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/"><img src="/images/logo_hu240a3cf0bd6402c880746328a9376fed_42031_0x70_resize_lanczos_2.png" alt="Consultation Recherche Données de Santé - CoReDS"></a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Ouvrir la barre de navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/"><img src="/images/logo_hu240a3cf0bd6402c880746328a9376fed_42031_0x70_resize_lanczos_2.png" alt="Consultation Recherche Données de Santé - CoReDS"></a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/entreprendre/"><span>Commencer un projet</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/suivremonprojet/"><span>Suivre son projet</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#outils"><span>Boite à outils</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#publi"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#transparence"><span>Portail de transparence</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#people"><span>Qui sommes-nous ?</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Rechercher"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      

      

    </ul>

  </div>
</nav>


  </div>

  <div class="page-body">
    <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span ><a href="/author/mas-jean-louis/">Mas Jean-Louis</a></span>, <span ><a href="/author/derumeaux-genevieve/">Derumeaux Genevieve</a></span>, <span ><a href="/author/guillon-benoit/">Guillon Benoit</a></span>, <span ><a href="/author/massardier-evelyne/">Massardier Evelyne</a></span>, <span ><a href="/author/hosseini-hassan/">Hosseini Hassan</a></span>, <span ><a href="/author/mechtouff-laura/">Mechtouff Laura</a></span>, <span ><a href="/author/arquizan-caroline/">Arquizan Caroline</a></span>, <span ><a href="/author/bejot-yannick/">Bejot Yannick</a></span>, <span ><a href="/author/vuillier-fabrice/">Vuillier Fabrice</a></span>, <span ><a href="/author/detante-olivier/">Detante Olivier</a></span>, <span ><a href="/author/guidoux-celine/">Guidoux Celine</a></span>, <span ><a href="/author/canaple-sandrine/">Canaple Sandrine</a></span>, <span ><a href="/author/vaduva-claudia/">Vaduva Claudia</a></span>, <span ><a href="/author/dequatre-ponchelle-nelly/">Dequatre-Ponchelle Nelly</a></span>, <span ><a href="/author/sibon-igor/">Sibon Igor</a></span>, <span ><a href="/author/garnier-pierre/">Garnier Pierre</a></span>, <span ><a href="/author/ferrier-anna/">Ferrier Anna</a></span>, <span ><a href="/author/timsit-serge/">Timsit Serge</a></span>, <span ><a href="/author/robinet-borgomano-emmanuelle/">Robinet-Borgomano Emmanuelle</a></span>, <span ><a href="/author/sablot-denis/">Sablot Denis</a></span>, <span ><a href="/author/lacour-jean-christophe/">Lacour Jean-Christophe</a></span>, <span ><a href="/author/zuber-mathieu/">Zuber Mathieu</a></span>, <span ><a href="/author/favrole-pascal/">Favrole Pascal</a></span>, <span ><a href="/author/pinel-jean-francois/">Pinel Jean-Francois</a></span>, <span ><a href="/author/apoil-marion/">Apoil Marion</a></span>, <span ><a href="/author/reiner-peggy/">Reiner Peggy</a></span>, <span ><a href="/author/lefebvre-catherine/">Lefebvre Catherine</a></span>, <span ><a href="/author/guerin-patrice/">Guerin Patrice</a></span>, <span ><a href="/author/piot-christophe/">Piot Christophe</a></span>, <span ><a href="/author/rossi-roland/">Rossi Roland</a></span>, <span ><a href="/author/dubois-rande-jean-luc/">Dubois-Rande Jean-Luc</a></span>, <span ><a href="/author/eicher-jean-christophe/">Eicher Jean-Christophe</a></span>, <span ><a href="/author/meneveau-nicolas/">Meneveau Nicolas</a></span>, <span ><a href="/author/lusson-jean-rene/">Lusson Jean-Rene</a></span>, <span ><a href="/author/bertrand-bernard/">Bertrand Bernard</a></span>, <span ><a href="/author/schleich-jean-marc/">Schleich Jean-Marc</a></span>, <span ><a href="/author/godart-francois/">Godart Francois</a></span>, <span ><a href="/author/thambo-jean-benoit/">Thambo Jean-Benoit</a></span>, <span ><a href="/author/leborgne-laurent/">Leborgne Laurent</a></span>, <span ><a href="/author/michel-patrik/">Michel Patrik</a></span>, <span ><a href="/author/pierard-luc/">Pierard Luc</a></span>, <span ><a href="/author/turc-guillaume/">Turc Guillaume</a></span>, <span ><a href="/author/barthelet-martine/">Barthelet Martine</a></span>, <span ><a href="/author/charles-nelson-anais/">Charles-Nelson Anais</a></span>, <span ><a href="/author/weimar-christian/">Weimar Christian</a></span>, <span ><a href="/author/moulin-thierry/">Moulin Thierry</a></span>, <span ><a href="/author/juliard-jean-michel/">Juliard Jean-Michel</a></span>, <span ><a href="/author/chatellier-gilles/">Chatellier Gilles</a></span>, <span ><a href="/author/domigo-v/">Domigo V</a></span>, <span ><a href="/author/guiraud-v/">Guiraud V</a></span>, <span ><a href="/author/touze-e/">Touze E</a></span>, <span ><a href="/author/calvet-d/">Calvet D</a></span>, <span ><a href="/author/lamy-c/">Lamy C</a></span>, <span ><a href="/author/teiger-e/">Teiger E</a></span>, <span ><a href="/author/dubois-rande-j-l/">Dubois-Rande J-L</a></span>, <span ><a href="/author/aubry-p/">Aubry P</a></span>, <span ><a href="/author/varenne-o/">Varenne O</a></span>, <span ><a href="/author/menacer-s/">Menacer S</a></span>, <span ><a href="/author/sroussi-m/">Sroussi M</a></span>, <span ><a href="/author/nana-a/">Nana A</a></span>, <span ><a href="/author/cabanes-l/">Cabanes L</a></span>, <span ><a href="/author/schunck-a/">Schunck A</a></span>, <span ><a href="/author/herisson-f/">Herisson F</a></span>, <span ><a href="/author/de-gaalon-s/">De Gaalon S</a></span>, <span ><a href="/author/sevin-m/">Sevin M</a></span>, <span ><a href="/author/langlard-j-m/">Langlard J-M</a></span>, <span ><a href="/author/piriou-n/">Piriou N</a></span>, <span ><a href="/author/jaafar-p/">Jaafar P</a></span>, <span ><a href="/author/dhere-b/">d&#39;Here B</a></span>, <span ><a href="/author/stepowski-d/">Stepowski D</a></span>, <span ><a href="/author/bauer-f/">Bauer F</a></span>, <span ><a href="/author/duval-a-m/">Duval A-M</a></span>, <span ><a href="/author/lim-p/">Lim P</a></span>, <span ><a href="/author/nighoghossian-n/">Nighoghossian N</a></span>, <span ><a href="/author/derex-l/">Derex L</a></span>, <span ><a href="/author/cho-t/">Cho T</a></span>, <span ><a href="/author/rioufol-g/">Rioufol G</a></span>, <span ><a href="/author/thibaut-h/">Thibaut H</a></span>, <span ><a href="/author/thivolet-s/">Thivolet S</a></span>, <span ><a href="/author/mourand-i/">Mourand I</a></span>, <span ><a href="/author/sportouch-c/">Sportouch C</a></span>, <span ><a href="/author/cade-s/">Cade S</a></span>, <span ><a href="/author/cransac-f/">Cransac F</a></span>, <span ><a href="/author/giroud-m/">Giroud M</a></span>, <span ><a href="/author/lhuillier-i/">L&#39;Huillier I</a></span>, <span ><a href="/author/chopard-r/">Chopard R</a></span>, <span ><a href="/author/descotes-genon-v/">Descotes-Genon V</a></span>, <span ><a href="/author/garambois-k/">Garambois K</a></span>, <span ><a href="/author/saunier-c/">Saunier C</a></span>, <span ><a href="/author/brochet-e/">Brochet E</a></span>, <span ><a href="/author/mazighi-m/">Mazighi M</a></span>, <span ><a href="/author/meseguer-e/">Meseguer E</a></span>, <span ><a href="/author/messika-zeitoun-d/">Messika-Zeitoun D</a></span>, <span ><a href="/author/cabrejo-l/">Cabrejo L</a></span>, <span ><a href="/author/lavallee-p/">Lavallee P</a></span>, <span ><a href="/author/lepage-l/">Lepage L</a></span>, <span ><a href="/author/amarenco-p/">Amarenco P</a></span>, <span ><a href="/author/bugnicourt-j-m/">Bugnicourt J-M</a></span>, <span ><a href="/author/godefroy-o/">Godefroy O</a></span>, <span ><a href="/author/rey-c/">Rey C</a></span>, <span ><a href="/author/guillaumont-m-p/">Guillaumont M-P</a></span>, <span ><a href="/author/trojette-f/">Trojette F</a></span>, <span ><a href="/author/malaquin-d/">Malaquin D</a></span>, <span ><a href="/author/couvreur-g/">Couvreur G</a></span>, <span ><a href="/author/golfier-v/">Golfier V</a></span>, <span ><a href="/author/plurien-f/">Plurien F</a></span>, <span ><a href="/author/taldir-g/">Taldir G</a></span>, <span ><a href="/author/lucas-c/">Lucas C</a></span>, <span ><a href="/author/cordonnier-c/">Cordonnier C</a></span>, <span ><a href="/author/henon-h/">Henon H</a></span>, <span ><a href="/author/dumont-f/">Dumont F</a></span>, <span ><a href="/author/leys-d/">Leys D</a></span>, <span ><a href="/author/richardson-m/">Richardson M</a></span>, <span ><a href="/author/polge-a-s/">Polge A-S</a></span>, <span ><a href="/author/montaigne-d/">Montaigne D</a></span>, <span ><a href="/author/coisne-a/">Coisne A</a></span>, <span ><a href="/author/rouanet-f/">Rouanet F</a></span>, <span ><a href="/author/renou-p/">Renou P</a></span>, <span ><a href="/author/reant-p/">Reant P</a></span>, <span ><a href="/author/laffite-s/">Laffite S</a></span>, <span ><a href="/author/roudaut-r/">Roudaut R</a></span>, <span ><a href="/author/comtet-c/">Comtet C</a></span>, <span ><a href="/author/delsart-d/">Delsart D</a></span>, <span ><a href="/author/bourgois-n/">Bourgois N</a></span>, <span ><a href="/author/clavelou-p/">Clavelou P</a></span>, <span ><a href="/author/rouhart-f/">Rouhart F</a></span>, <span ><a href="/author/le-cadet-e/">Le Cadet E</a></span>, <span ><a href="/author/tirel-a/">Tirel A</a></span>, <span ><a href="/author/mocquard-y/">Mocquard Y</a></span>, <span ><a href="/author/jobic-y/">Jobic Y</a></span>, <span ><a href="/author/le-ven-f/">Le Ven F</a></span>, <span ><a href="/author/pouliquen-m-c/">Pouliquen M-C</a></span>, <span ><a href="/author/milandre-l/">Milandre L</a></span>, <span ><a href="/author/laksiri-n/">Laksiri N</a></span>, <span ><a href="/author/fraisse-a/">Fraisse A</a></span>, <span ><a href="/author/habib-g/">Habib G</a></span>, <span ><a href="/author/chalvignac-v/">Chalvignac V</a></span>, <span ><a href="/author/thuny-f/">Thuny F</a></span>, <span ><a href="/author/targosz-f/">Targosz F</a></span>, <span ><a href="/author/runavot-g/">Runavot G</a></span>, <span ><a href="/author/chopat-p/">Chopat P</a></span>, <span ><a href="/author/sultan-p/">Sultan P</a></span>, <span ><a href="/author/richard-s/">Richard S</a></span>, <span ><a href="/author/ducrocq-x/">Ducrocq X</a></span>, <span ><a href="/author/marcon-f/">Marcon F</a></span>, <span ><a href="/author/selton-suty-m-c/">Selton-Suty M C</a></span>, <span ><a href="/author/huttin-o/">Huttin O</a></span>, <span ><a href="/author/bruandet-m/">Bruandet M</a></span>, <span ><a href="/author/tamazyan-r/">Tamazyan R</a></span>, <span ><a href="/author/antakly-y/">Antakly Y</a></span>, <span ><a href="/author/garcon-p/">Garcon P</a></span>, <span ><a href="/author/serfaty-j/">Serfaty J</a></span>, <span ><a href="/author/hammoudi-n/">Hammoudi N</a></span>, <span ><a href="/author/donal-e/">Donal E</a></span>, <span ><a href="/author/lelong-b/">Lelong B</a></span>, <span ><a href="/author/chabanne-c/">Chabanne C</a></span>, <span ><a href="/author/viader-f/">Viader F</a></span>, <span ><a href="/author/cogez-j/">Cogez J</a></span>, <span ><a href="/author/labombarda-f/">Labombarda F</a></span>, <span ><a href="/author/saloux-e/">Saloux E</a></span>, <span ><a href="/author/buffon-f/">Buffon F</a></span>, <span ><a href="/author/baudet-m/">Baudet M</a></span>, <span ><a href="/author/logeart-d/">Logeart D</a></span>, <span ><a href="/author/bataille-m/">Bataille M</a></span>, <span ><a href="/author/godard-f/">Godard F</a></span>, <span ><a href="/author/biausque-f/">Biausque F</a></span>, <span ><a href="/author/lefetz-y/">Lefetz Y</a></span>, <span ><a href="/author/clement-dupont-m/">Clement-Dupont M</a></span>, <span ><a href="/author/zegarac-v/">Zegarac V</a></span>, <span ><a href="/author/schmitz-t/">Schmitz T</a></span>, <span ><a href="/author/plicht-b/">Plicht B</a></span>, <span ><a href="/author/eissmann-m/">Eissmann M</a></span>, <span ><a href="/author/mahabadi-a/">Mahabadi A</a></span>, <span ><a href="/author/obadia-m/">Obadia M</a></span>, <span ><a href="/author/iglesias-benyounes-n/">Iglesias Benyounes N</a></span>, <span ><a href="/author/macian-f/">Macian F</a></span>, <span ><a href="/author/darodes-n/">Darodes N</a></span>, <span ><a href="/author/tanguy-b/">Tanguy B</a></span>, <span ><a href="/author/mohty-d/">Mohty D</a></span>, <span ><a href="/author/vuillemet-f/">Vuillemet F</a></span>, <span ><a href="/author/onea-r/">Onea R</a></span>, <span ><a href="/author/greciano-s/">Greciano S</a></span>, <span ><a href="/author/roth-o/">Roth O</a></span>, <span ><a href="/author/neau-j-p/">Neau J-P</a></span>, <span ><a href="/author/quillet-l/">Quillet L</a></span>, <span ><a href="/author/christiaens-l/">Christiaens L</a></span>, <span ><a href="/author/saudeau-d/">Saudeau D</a></span>, <span ><a href="/author/patat-f/">Patat F</a></span>, <span ><a href="/author/singer-o/">Singer O</a></span>, <span ><a href="/author/fichtlscherer-s/">Fichtlscherer S</a></span>, <span ><a href="/author/pico-f/">Pico F</a></span>, <span ><a href="/author/charbonnel-c/">Charbonnel C</a></span>, <span ><a href="/author/durand-zaleski-i/">Durand-Zaleski I</a></span>, <span ><a href="/author/woimant-f/">Woimant F</a></span>, <span ><a href="/author/finet-g/">Finet G</a></span>, <span ><a href="/author/mounier-vehier-f/">Mounier-Vehier F</a></span>, <span ><a href="/author/rodier-g/">Rodier G</a></span>, <span ><a href="/author/ernande-l/">Ernande L</a></span>, <span ><a href="/author/lievre-m/">Lievre M</a></span>, <span ><a href="/author/andrieux-chantal/">Andrieux Chantal</a></span>, <span ><a href="/author/sauret-isabelle/">Sauret Isabelle</a></span>, <span ><a href="/author/bruyere-clemence/">Bruyere Clemence</a></span>, <span ><a href="/author/chenu-romain/">Chenu Romain</a></span>, <span ><a href="/author/trinquart-ludovic/">Trinquart Ludovic</a></span>, <span ><a href="/author/alsaleh-khaled/">Alsaleh Khaled</a></span>, <span ><a href="/author/bousry-djennat/">Bousry Djennat</a></span>, <span ><a href="/author/branco-sonia/">Branco Sonia</a></span>, <span ><a href="/author/brussieux-maxime/">Brussieux Maxime</a></span>, <span ><a href="/author/greaud-cecile/">Greaud Cecile</a></span>, <span ><a href="/author/kacher-zineb/">Kacher Zineb</a></span>, <span ><a href="/author/loret-laurie/">Loret Laurie</a></span>, <span ><a href="/author/niranjani-mahendran/">Niranjani Mahendran</a></span>, <span ><a href="/author/olivier-audrey/">Olivier Audrey</a></span>, <span ><a href="/author/pigeat-romain/">Pigeat Romain</a></span>, <span ><a href="/author/sahuc-karen/">Sahuc Karen</a></span>, <span ><a href="/author/djadi-prat-juliette/">Djadi-Prat Juliette</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    2017-09-01
  </span>
  

  

  

  
  
  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    
    <h3>Résumé</h3>
    <p class="pub-abstract">BACKGROUND:Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.METHODS:In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.RESULTS:A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P&lt;0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.CONCLUSIONS:Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .).</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Article de revue
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">The New England journal of medicine, <a href="https://doi.org/10.1056/NEJMoa1705915">https://doi.org/10.1056/NEJMoa1705915</a></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"><p><a href="https://www.scimagojr.com/journalsearch.php?q=15847&amp;tip=sid&amp;exact=no" title="SCImago Journal &amp; Country Rank"><img border="0" src="https://www.scimagojr.com/journal_img.php?id=15847" alt="SCImago Journal &amp; Country Rank"  /></a>
<strong>SCImago Journal Rank (SJR)</strong> est un indicateur de notoriété des revues indexées à partir de 1996 dans la base de données Scopus de l’éditeur Elsevier. Le SJR a été créé par le groupe de travail SCImago Research Group (SRG) de l’Université de Grenade et Alcana de Henares en Espagne.</p>
<p>Le SJR d’une revue est le nombre de fois où un article de cette revue est cité par d’autres articles pendant les 3 ans qui suivent sa publication, chaque citation reçue étant pondérée par la notoriété de la revue citante. Les articles « citants » sont issus d’autres revues et de la revue notée. Les citations d’articles de la revue par des articles de cette même revue (on parle d’autocitations) sont ainsi incluses dans le calcul du SJR, mais dans une limite de 35 %. Dans le calcul du SJR, le nombre de citations reçues par une revue est rapporté au nombre d’articles publiés par la revue au cours des 3 années qui précèdent.</p>
<p>L&rsquo;ensemble des revues a été classé en fonction de leur SJR et divisé en quatre groupes égaux, quartiles. Q1 (vert) comprend le quart des journaux avec les valeurs les plus élevées, Q2 (jaune) les deuxièmes valeurs les plus élevées, Q3 (orange) les troisièmes valeurs les plus élevées et Q4 (rouge) les valeurs les plus faibles.</p>
<p>Différent entre le <strong>SJR</strong> et l'<strong>Impact Factor</strong> :</p>
<ul>
<li>Le SJR est calculé pour une période de citation de 3 ans. Il tient compte de la notoriété des revues citantes. Il inclut de façon limitée les autocitations d’une revue ;</li>
<li>L&rsquo;Impact Factor est calculé pour une période de citation de 2 ans. Il ne tient pas compte de la notoriété des revues citantes. Il inclut toutes les autocitations d’une revue.</li>
</ul>
</div>

    








<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/&amp;text=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke." target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/&amp;t=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke." target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke.&amp;body=https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/&amp;title=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke." target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke.%20https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://www.coreds.com/publication/2017-09-01_patent_foramen_ovale/&amp;title=Patent%20Foramen%20Ovale%20Closure%20or%20Anticoagulation%20vs.%20Antiplatelets%20after%20Stroke." target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  














  
  





  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">
  

  <p class="powered-by">
    <code>2021</code> - <strong>CoReDS</strong>
  </p>

  
  






  <p class="powered-by">
    
    
    
    Published with
    <a href="https://wowchemy.com" target="_blank" rel="noopener">Wowchemy</a>  —
    the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">
    open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Citation</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copier
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Télécharger
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>

      
      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      

      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/highlight.min.js" integrity="sha512-TDKKr+IvoqZnPzc3l35hdjpHD0m+b2EC2SrLEgKDRWpxf2rFCxemkgvJ5kfU48ip+Y+m2XVKyOCD85ybtlZDmw==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/r.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/latex.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.js" integrity="sha512-SeiQaaDh73yrb56sTW/RgVdi/mMqNeM2oBwubFHagc5BkixSpP1fvqF47mKzPGWYSSy4RwbBunrJBQ4Co8fRWA==" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"Aucun résultat n'a été trouvé","placeholder":"Recherche...","results":"Résultats trouvés"};
      const content_type = {
        'post': "Posts",
        'project': "Projets",
        'publication' : "Publications",
        'talk' : "Présentations",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/wowchemy.min.d9d80f811e95b4b4f6df1eaaf297b05f.js"></script>

    






</body>
</html>
